Click image to view it in full size

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs. The rapid adoption of AI/ML algorithms and platforms to structure and utilize electronic health records (EHRs) allows the industry to tap into a vast, rich, and highly relevant data source that holds tremendous potential in improving the global clinical trial landscape.

Incorporating integrated AI-driven solutions in clinical trial design and patient retention will ease the go-to-market strategy for various CROs and pharma players as they will reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, as well as engagement through interactive platforms thus ensuring higher retention. AI technologies bring fundamental innovations for transforming clinical trials, such as collecting and analyzing real-world data, seamlessly combining phases I and II of clinical trials, and developing novel patient-centered endpoints. Together, big technology providers and pharmaceutical start-ups are setting the course for more effective clinical trials in the future.